Real world effectiveness and safety of pazopanib and everolimus in metastatic renal cell carcinoma: first interim analysis of the PAZOREAL study

Bedke J, Welslau M, Boegemann M, Schostak M, Hering-Schubert C, Petzoldt A, Wolf T, Schleicher J, Doehn C, Gruellich C, Gruenwald V, Steiner T, Ehness R, Goebell P (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Oncology Research and Treatment Karger Publishers

Book Volume: 40

Pages Range: 97-+

Authors with CRIS profile

Peter Goebell Urologische Klinik

Involved external institutions

HELIOS Kliniken

Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School

Germany (DE) Klinikum Stuttgart

Germany (DE) Novartis AG

Switzerland (CH) Universitätsklinikum Heidelberg

Germany (DE) Urologikum Lübeck

Germany (DE) Otto-von-Guericke-Universität Magdeburg

Germany (DE) Eberhard Karls Universität Tübingen

Germany (DE) Westfälische Wilhelms-Universität (WWU) Münster

Germany (DE) Universitätsklinikum Jena

Germany (DE)

How to cite

APA:

Bedke, J., Welslau, M., Boegemann, M., Schostak, M., Hering-Schubert, C., Petzoldt, A.,... Goebell, P. (2017). Real world effectiveness and safety of pazopanib and everolimus in metastatic renal cell carcinoma: first interim analysis of the PAZOREAL study. (pp. 97-+).

MLA:

Bedke, J., et al. "Real world effectiveness and safety of pazopanib and everolimus in metastatic renal cell carcinoma: first interim analysis of the PAZOREAL study." 2017. 97-+.

BibTeX: Download